Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality. | J Immunother Cancer | 2025 | 39915004 | PubTator, text mining | PubMed |
| Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma. | J Clin Oncol | 2025 | 39883889 | PubTator, text mining | PubMed |
| In Situ Bioconjugation of Synthetic Peptides onto Universal Chimeric Antigen Receptor T Cells for Targeted Cancer Immunotherapies. | ACS Nano | 2025 | 39869930 | PubTator, text mining | PubMed |
| Ferroptosis Transcriptional Regulation and Prognostic Impact in Medulloblastoma Subtypes Revealed by RNA-Seq. | Antioxidants (Basel) | 2025 | 39857430 | PubTator, text mining | PubMed |
| Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. | Signal Transduct Target Ther | 2025 | 39809749 | PubTator, text mining | PubMed |
| A framework integrating multiscale in-silico modeling and experimental data predicts CD33CAR-NK cytotoxicity across target cell types. | bioRxiv | 2025 | 39803543 | PubTator, text mining | PubMed |
| ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion. | Cancer Res Treat | 2025 | 39701088 | PubTator, text mining | PubMed |
| Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. | Blood Adv | 2025 | 39631066 | PubTator, text mining | PubMed |
| Novel FRET-based Immunological Synapse Biosensor for the Prediction of Chimeric Antigen Receptor-T Cell Function. | Small Methods | 2025 | 39258379 | PubTator, text mining | PubMed |
| A multi-scale semi-mechanistic CK/PD model for CAR T-cell therapy. | Front Syst Biol | 2024 | 40809127 | PubTator, text mining | PubMed |
| The impact of CD3ζ ITAM multiplicity and sequence on CAR T-cell survival and function. | Front Immunol | 2024 | 39885989 | PubTator, text mining | PubMed |
| The current socioeconomic and regulatory landscape of immune effector cell therapies. | Front Med (Lausanne) | 2024 | 39697210 | PubTator, text mining | PubMed |
| Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen. | J Immunother Cancer | 2024 | 39694704 | PubTator, text mining | PubMed |
| De novo functional discovery of peptide-MHC restricted CARs from recombinase-constructed large-diversity monoclonal T cell libraries. | bioRxiv | 2024 | 39651191 | PubTator, text mining | PubMed |
| Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. | J Immunother Cancer | 2024 | 39622582 | PubTator, text mining | PubMed |
| Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity. | JCI Insight | 2024 | 39576012 | PubTator, text mining | PubMed |
| MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. | J Immunother Cancer | 2024 | 39572159 | PubTator, text mining | PubMed |
| Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants. | Curr Opin Biotechnol | 2024 | 39504625 | PubTator, text mining | PubMed |
| CRISPR-Cas9-mediated homology-directed repair for precise gene editing. | Mol Ther Nucleic Acids | 2024 | 39494147 | PubTator, text mining | PubMed |
| MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. | Signal Transduct Target Ther | 2024 | 39438476 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=5